Labcorp launches pTau-217/Beta Amyloid 42 Ratio test for Alzheimer’s

Labcorp (LH) announced the nationwide launch of its pTau-217/Beta Amyloid 42 Ratio, a powerful new blood-based biomarker test to aid in the diagnosis of Alzheimer’s disease. The new test further expands Labcorp’s leading blood-based biomarker portfolio for Alzheimer’s disease and dementia. The pTau-217/Beta Amyloid 42 Ratio supports neurologists, dementia specialists and their patients by offering results that are comparable to positron emission tomography imaging and cerebrospinal fluid testing obtained through lumbar puncture. Labcorp’s test meets performance criteria to confirm the presence of amyloid pathology consistent with Alzheimer’s disease, and, in connection with clinical findings, supports an accelerated path to diagnosis in patients being evaluated for Alzheimer’s disease and other causes of cognitive decline.